乳腺癌耐药蛋白对急性髓系白血病耐药性的临床研究  

The Clinical Research of Breast Cancer Resistance Protein Gene in Acute Myeloid Leukemia

作　　者：周迪[1] 石张镇[1] 杨永净[2] 刁建东[1] 白元松[1] 卢振霞[1] ZHOU Di;SHI Zhangzhen;YANG Yong-jing(Department of Hematology and Oncology,China-Japan Union Hospital of Jilin University,Changchun130033,China)

机构地区：[1]吉林大学中日联谊医院血液肿瘤科,吉林长春130033 [2]吉林省肿瘤医院放疗一科,吉林长春130012

出　　处：《中国实验诊断学》2021年第10期1469-1473,共5页Chinese Journal of Laboratory Diagnosis

基　　金：长春市科技计划项目(06GG63)。

摘　　要：目的探讨乳腺癌耐药蛋白在急性髓系白血病(AML)患者耐药性中的作用。方法以临床确诊AML的患者骨髓单个核细胞作为研究对象,按照疗程分为初治组(n=12)、复发组(n=8),按照疗效分为敏感组(n=9)、耐药组(n=11)。应用RT-PCR检测BCRP基因的相对表达量,利用流式细胞术检测骨髓单个核细胞的BCRP蛋白水平,并应用MTT法检测骨髓单个核细胞对柔红霉素的体外药物敏感性。结果以BCRP表型分组,检测BCRP表达阴性及阳性的AML细胞体外药物敏感性,结果显示在0.125倍PPC柔红霉素作用下,BCRP阴性组的细胞抑制率显著高于BCRP阳性组的细胞抑制率(24.09±18.68vs 1.99±0.80,P=0.001)。在2倍PPC柔红霉素作用下,BCRP阴性组的抑制率也显著高于BCRP阳性组的抑制率(39.26±15.25vs 20.58±3.67,P=0.002)。结论 BCRP的过度表达可导致抗肿瘤药物体外敏感性降低,BCRP可能与AML的临床耐药有关。Objective To investigate the relation between breast cancer resistance protein(BCRP)and the clinical features,drug susceptibility,prognosis in acute myeloid leukemia(AML).Methods Bone marrow mononuclear cells from patients without AML were used as control group,and bone marrow mononuclear cells from patients with clinically diagnosed AML were used as AML group.The AML group was divided into the initial treatment group(n=12)and the recurrent group(n=8)according to the course of treatment,and the sensitive group(n=9)and the resistant group(n=11)according to the efficacy.Reverse transcription-PCR(RT-PCR)was used to analyze the BCRP gene expression in bone marrow cells from 5normal controls and 20AML patients,and flow cytometry,MTT colorimetric assay were used to detect the BCRP protein level and in vitro drug sensitivity in bone marrow cells from 20AML patients.Results In vitro drug sensitivity of AML cells with negative and positive BCRP expression was detected by BCRP phenotype grouping.The results showed that the inhibition rate of BCRP negative group was significantly higher than that of BCRP positive group(24.09±18.68vs 1.99±0.80,P=0.001)under 0.125times PPC Daunorubicin.The inhibition rate in the BCRP negative group was significantly higher than that in the BCRP positive group(39.26±15.25vs 20.58±3.67,P=0.002)under 2times PPC Daunorubicin.Conclusion BCRP mRNA over-expression can lead to reduced susceptibility in vitro antineoplastic agents,BCRP may be associated with clinical resistance in AML relapse.

关 键 词：急性髓细胞白血病 乳腺癌耐药蛋白基因 半定量逆转录-聚合酶链反应 流式细胞术 MTT比色法 

分 类 号：R733.71[医药卫生—肿瘤]